Chronic Obstructive Pulmonary Disease (COPD)NCT02629055
Respiratory EMG for NIV Titration in Stable COPD Patients
A study testing Respiratory EMG in people with Chronic Obstructive Pulmonary Disease (COPD), run by University Medical Center Groningen at 1 site in Netherlands.
Trial summary
The aim of the present study is to investigate whether additional titration on surface electromyography (EMG) of the diaphragm and intercostal muscles improves the outcome of chronic non-invasive ventilation in patients with COPD and stable chronic hypercapnic respiratory failure in terms of better gas exchange after… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Chronic Obstructive Pulmonary Disease (COPD)
- What is being tested?
- Respiratory EMG
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1 participants
- Where
- 1 siteNetherlands
- Study dates
- Nov 2015to Jun 2016
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Chronic Obstructive Pulmonary Disease (COPD) Global initiative of chronic Obstructive Lung Diseases (GOLD) stage III or IV (FEV1 <50 % predicted, FEV1/forced expiratory volume (FVC) < 70% predicted)
- Indication for the initiation of chronic NIV: PaCO2 >6.0 kilopascal (kPa) at rest during daytime.
- Stable COPD (pH >7.35, no exacerbation in the past two weeks)
- Age >18 years
Who cannot join
- Respiratory insufficiency of any other cause.
- Already initiated on chronic NIV.
Trial locations and contacts
1 site in 1 country.
Netherlands1 site
University Medical Center Groningen
Groningen, Provincie Groningen, 9700RB
About this study
Official title: EMG Measurements of Respiratory Muscles for the Titration of Nocturnal Non-invasive Ventilation in Stable Chronic Obstructive Pulmonary Disease Patients: A Randomized Controlled Trial
The aim of the present study is to investigate whether additional titration on surface electromyography (EMG) of the diaphragm and intercostal muscles improves the outcome of chronic non-invasive ventilation in patients with COPD and stable chronic hypercapnic respiratory failure in terms of better gas exchange after six weeks, lung function, patient comfort and compliance, and less patient ventilator asynchrony. Therefore, the investigators set up a randomized, two-armed crossover trial comparing regular titration with additional respiratory EMG titration of NIV.
Read the detailed description
Rationale:
Long-term application of nocturnal non-invasive ventilation (NIV) in stable hypercapnic chronic obstructive pulmonary disease (COPD) patients has long been controversial as study results were not unequivocal. However, in the past 7 years, with a change in ventilatory strategy, clear benefits of chronic NIV have been shown in COPD patients with chronic hypercapnic respiratory failure (CHRF), though only in stable disease. As a consequence, this so called high-intensity NIV, which is the concept of using higher positive inspiratory airway pressures (IPAP) levels than used in most of the older trials in addition to controlled ventilation with higher backup breathing frequencies aiming for maximal arterial carbon dioxide (PaCO2) reduction, has gained increasing attention.
However, it is unknown how high-intensity NIV works, and how to titrate the optimal IPAP and optimal backup breathing frequency. Measuring respiratory muscle activity might be a way to titrate NIV in COPD.
Objective:
The aim of the present study is to investigate whether additional titration on surface electromyography (EMG) of the diaphragm and intercostal muscles improves outcomes of chronic NIV in patients with COPD and stable CHRF in terms of better gas exchange after six weeks, lung function, patient comfort and compliance and less patient-ventilator asynchrony (PVA).
Study design:
A randomized, two-armed, crossover trial comparing regular titration with additional respiratory EMG titration of NIV in stable hypercapnic COPD.
One group will be initiated on NIV according to standard care protocol. For the other group, additional EMG measures whilst on NIV will be made to titrate NIV.
Protocol Regular NIV-set up (both groups) Subjects are initiated on NIV according to our own local treatment protocol. NIV is initiated by a registered nurse of our home mechanical ventilation (HMV) centre. Effectiveness is measured with transcutaneous measurements of carbon dioxide (PtCO2).
NIV is supplied through a pressure cycled ventilator, applying both inspiratory airway pressure and expiratory airway pressure to the patient (BiPAP; Synchrony, Respironics, incorporated., Murrysville, USA). A nasal or full face mask (Mirage mask, ResMed Ltd, UK) of proper size is used. The ventilator is set in a spontaneous/ time mode (S/T), with a backup frequency. If needed O2 was added to obtain a saturation of ≥ 90%. A humidifier (HC 150 Fisher \& Paykel Healthcare, Australia) is used if needed. In general, the nurse aims to reach a setting with high inspiratory pressures and a moderate breathing backup frequency, with good patient comfort.
Start of the study Patients will be included in the study once they is used to the mask, can sleep at least 6 hours with the ventilator and settings are set as is usual in daily clinical practice. This means that the initial NIV settings are optimized according to the results of an overnight PtCO2 and patient comfort. In daily practice, the specialized nurses of the HMV centre already aim to increase the inspiratory pressure to the highest pressure that is still comfortable for the patient, so that all patients will already be at their highest tolerable pressure.
Once patients agree to participate, a 15-minute EMG measurement is done in all patients while they are ventilated with the settings at that particular moment. Furthermore, patients are asked to complete the severe respiratory insufficiency (SRI) questionnaire.
In the "nurse titrated NIV" group, no additional changes are made to the ventilatory settings. In the "EMG titrated NIV" group, after a 15-minute EMG with the ventilatory settings set by the nurse, the nurse will decrease the backup breathing frequency set by the ventilator by steps of 2 breaths/min to 8 breaths/min (to achieve a pressure support mode of ventilation (completely triggered by the patient)) and then again up to a frequency 2 breaths/min above their spontaneous breathing frequency while on the ventilator (to achieve a controlled mode of ventilation). Each frequency will be measured for 10 minutes, so that the total titration will take about 60-80 minutes. EMG measurements will be done throughout the whole session and will be analyzed the same day. Then, the setting is chosen with the lowest EMG activity and least PVA. The next night an EMG measurement is performed at the chosen setting.
6 weeks After 6 weeks, the overnight EMG measurement is repeated in all patients. Furthermore, a nocturnal PtCO2 measurement is performed, patients are asked to rate how comfortable the patient is with the settings and are asked to fill in the SRI, lung function is assessed and the number of hours use per night is read from the ventilator counting reading. After these measurements are performed, patients are directed to the other titration arm. In patients initially titrated by the nurse, an EMG frequency titration is performed as described above. In the patients initially titrated additionally on the EMG, the investigators will reset the ventilator to the settings applied by the nurse initially.
12 weeks After 12 weeks, the nocturnal EMG measurement, the nocturnal transcutaneous CO2 measurement, the comfort score, the SRI, lung function assessment and compliance rating are repeated in all patients.
- Being tested
- Respiratory EMG
- Keywords
- Non-invasive ventilation, Respiratory electromyography
- Medical subject headings
- Pulmonary Disease, Chronic Obstructive
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Respiratory EMGOther
Titration of non-invasive ventilation on surface respiratory muscle activity
| Study group | Role | What they receive |
|---|---|---|
| Respiratory EMG | Experimental | Additional EMG measurements whilst on NIV will be used to guide the titration of NIV. Receives: Other: Respiratory EMG |
| Care as usual | No intervention | NIV will be initiated according to standard care protocol. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Nocturnal gas exchange (PCO2 (kPa))
PCO2 will be assessed with transcutaneous measurements (TOSCA, Linde Medical Sensors AG, Basel)
Measured: 6 weeks
Secondary outcomes (5)
Patient comfort measured with a Visual Analogue Scale
comfort with NIV setting, measured with a Visual Analogue Scale
Measured: 6 weeks
Health related quality of life measured with the Severe Respiratory Insufficiency (SRI) questionaire
Measured with the Severe Respiratory Insufficiency (SRI) questionaire
Measured: 6 weeks
Lung volumes
Total Lung Capacity (liters) and Residual Volume (liters))
Measured: 6 weeks
Respiratory muscle strength
Maximal inspiratory pressure (kPa)).
Measured: 6 weeks
Patient-Ventilator Asynchrony (PVA)
The investigators will assess PVA's by simultaneously comparing EMG recordings with pressure waves delivered by the ventilator. PVA's are measured as a percentage of the total number of delivered breaths
Measured: 6 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Dec 2015 (estimated)
- Study startNov 2015
- Primary completionJun 2016
- Study completionJun 2016
Why it stopped: Insufficient recruitment during the predefined time frame for the study
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Obstructive Pulmonary Disease (COPD)Studies of the same condition, open and under way.
- More trials run by University Medical Center GroningenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 1 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Medical Center Groningen
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Marieke Duiverman, University Medical Center Groningen
- Investigators
- Marieke L Duiverman, Dr, Principal investigator, University Medical Center Groningen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02629055
- Sponsor's protocol ID
- 2015/383
- Status last verified
- Jun 2016
- First submitted
- 1 Dec 2015
- Last updated
- 9 Jun 2016
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 9 Jun 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- EMG Measurements of Respiratory Muscles for the Titration of Nocturnal Non-invasive Ventilation in Stable Chronic Obstructive Pulmonary Disease Patients: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT02629055
- Acronym / sponsor ID
- 2015/383
- Keywords
- Non-invasive ventilation, Respiratory electromyography
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Insufficient recruitment during the predefined time frame for the study
- Enrolment
- 1 participants (actual)
- Lead sponsor
- University Medical Center GroningenUniversity, hospital or other
- Study start
- Nov 2015
- Primary completion
- Jun 2016 (actual)
- Study completion
- Jun 2016 (actual)
- First posted
- 11 Dec 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the present study is to investigate whether additional titration on surface electromyography (EMG) of the diaphragm and intercostal muscles improves the outcome of chronic non-invasive ventilation in patients with COPD and stable chronic hypercapnic respiratory failure in terms of better gas exchange after six weeks, lung function, patient comfort and compliance, and less patient ventilator asynchrony. Therefore, the investigators set up a randomized, two-armed crossover trial comparing regular titration with additional respiratory EMG titration of NIV.
Detailed description
Rationale:
Long-term application of nocturnal non-invasive ventilation (NIV) in stable hypercapnic chronic obstructive pulmonary disease (COPD) patients has long been controversial as study results were not unequivocal. However, in the past 7 years, with a change in ventilatory strategy, clear benefits of chronic NIV have been shown in COPD patients with chronic hypercapnic respiratory failure (CHRF), though only in stable disease. As a consequence, this so called high-intensity NIV, which is the concept of using higher positive inspiratory airway pressures (IPAP) levels than used in most of the older trials in addition to controlled ventilation with higher backup breathing frequencies aiming for maximal arterial carbon dioxide (PaCO2) reduction, has gained increasing attention.
However, it is unknown how high-intensity NIV works, and how to titrate the optimal IPAP and optimal backup breathing frequency. Measuring respiratory muscle activity might be a way to titrate NIV in COPD.
Objective:
The aim of the present study is to investigate whether additional titration on surface electromyography (EMG) of the diaphragm and intercostal muscles improves outcomes of chronic NIV in patients with COPD and stable CHRF in terms of better gas exchange after six weeks, lung function, patient comfort and compliance and less patient-ventilator asynchrony (PVA).
Study design:
A randomized, two-armed, crossover trial comparing regular titration with additional respiratory EMG titration of NIV in stable hypercapnic COPD.
One group will be initiated on NIV according to standard care protocol. For the other group, additional EMG measures whilst on NIV will be made to titrate NIV.
Protocol Regular NIV-set up (both groups) Subjects are initiated on NIV according to our own local treatment protocol. NIV is initiated by a registered nurse of our home mechanical ventilation (HMV) centre. Effectiveness is measured with transcutaneous measurements of carbon dioxide (PtCO2).
NIV is supplied through a pressure cycled ventilator, applying both inspiratory airway pressure and expiratory airway pressure to the patient (BiPAP; Synchrony, Respironics, incorporated., Murrysville, USA). A nasal or full face mask (Mirage mask, ResMed Ltd, UK) of proper size is used. The ventilator is set in a spontaneous/ time mode (S/T), with a backup frequency. If needed O2 was added to obtain a saturation of ≥ 90%. A humidifier (HC 150 Fisher \& Paykel Healthcare, Australia) is used if needed. In general, the nurse aims to reach a setting with high inspiratory pressures and a moderate breathing backup frequency, with good patient comfort.
Start of the study Patients will be included in the study once they is used to the mask, can sleep at least 6 hours with the ventilator and settings are set as is usual in daily clinical practice. This means that the initial NIV settings are optimized according to the results of an overnight PtCO2 and patient comfort. In daily practice, the specialized nurses of the HMV centre already aim to increase the inspiratory pressure to the highest pressure that is still comfortable for the patient, so that all patients will already be at their highest tolerable pressure.
Once patients agree to participate, a 15-minute EMG measurement is done in all patients while they are ventilated with the settings at that particular moment. Furthermore, patients are asked to complete the severe respiratory insufficiency (SRI) questionnaire.
In the "nurse titrated NIV" group, no additional changes are made to the ventilatory settings. In the "EMG titrated NIV" group, after a 15-minute EMG with the ventilatory settings set by the nurse, the nurse will decrease the backup breathing frequency set by the ventilator by steps of 2 breaths/min to 8 breaths/min (to achieve a pressure support mode of ventilation (completely triggered by the patient)) and then again up to a frequency 2 breaths/min above their spontaneous breathing frequency while on the ventilator (to achieve a controlled mode of ventilation). Each frequency will be measured for 10 minutes, so that the total titration will take about 60-80 minutes. EMG measurements will be done throughout the whole session and will be analyzed the same day. Then, the setting is chosen with the lowest EMG activity and least PVA. The next night an EMG measurement is performed at the chosen setting.
6 weeks After 6 weeks, the overnight EMG measurement is repeated in all patients. Furthermore, a nocturnal PtCO2 measurement is performed, patients are asked to rate how comfortable the patient is with the settings and are asked to fill in the SRI, lung function is assessed and the number of hours use per night is read from the ventilator counting reading. After these measurements are performed, patients are directed to the other titration arm. In patients initially titrated by the nurse, an EMG frequency titration is performed as described above. In the patients initially titrated additionally on the EMG, the investigators will reset the ventilator to the settings applied by the nurse initially.
12 weeks After 12 weeks, the nocturnal EMG measurement, the nocturnal transcutaneous CO2 measurement, the comfort score, the SRI, lung function assessment and compliance rating are repeated in all patients.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Respiratory EMG | Experimental | Other: Respiratory EMGAdditional EMG measurements whilst on NIV will be used to guide the titration of NIV. |
| Care as usual | No intervention | –NIV will be initiated according to standard care protocol. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Chronic Obstructive Pulmonary Disease (COPD) Global initiative of chronic Obstructive Lung Diseases (GOLD) stage III or IV (FEV1 <50 % predicted, FEV1/forced expiratory volume (FVC) < 70% predicted)
- Indication for the initiation of chronic NIV: PaCO2 >6.0 kilopascal (kPa) at rest during daytime.
- Stable COPD (pH >7.35, no exacerbation in the past two weeks)
- Age >18 years
Key exclusion criteria (2 listed)
- Respiratory insufficiency of any other cause.
- Already initiated on chronic NIV.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Respiratory EMGTitration of non-invasive ventilation on surface respiratory muscle activity | Other | Respiratory EMG |
Primary outcome
Nocturnal gas exchange (PCO2 (kPa))
Time frame: 6 weeks
PCO2 will be assessed with transcutaneous measurements (TOSCA, Linde Medical Sensors AG, Basel)
5 secondary outcomes
Patient comfort measured with a Visual Analogue Scale
Time frame: 6 weeks
Health related quality of life measured with the Severe Respiratory Insufficiency (SRI) questionaire
Time frame: 6 weeks
Lung volumes
Time frame: 6 weeks
Respiratory muscle strength
Time frame: 6 weeks
Patient-Ventilator Asynchrony (PVA)
Time frame: 6 weeks
Results and safety
The study was stopped early (reason given: Insufficient recruitment during the predefined time frame for the study). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jun 2016.
Related trials for Chronic Obstructive Pulmonary Disease (COPD)
Active, not recruiting
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
COPD, Smoking
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Not yet recruiting
The Aim of the Study is to Decipher the Alterations in Signalling Pathways of Skeletal Muscle Stem Cells (Satellite Cells (SCs)) in Individuals With COPD, as Well as to Examine the Effect of Exercise Training on SCs.
COPD (Chronic Obstructive Pulmonary Disease), Sarcopenia in Elderly
Not yet recruitingPhase 2
Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Active, not recruitingPhase 1
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
Pulmonary Disease, Chronic Obstructive
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Marieke L Duiverman, Dr principal investigator
University Medical Center Groningen
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Respiratory EMG in people with Chronic Obstructive Pulmonary Disease (COPD), run by University Medical Center Groningen at 1 site in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 9 Jun 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: Insufficient recruitment during the predefined time frame for the study). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Nocturnal gas exchange (PCO2 (kPa)) (time frame: 6 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jun 2016.